Asset Details
Do you wish to reserve the book?
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
Do you wish to request the book?
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
2018
Overview
Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.
Publisher
Future Medicine Ltd
Subject
/ Alkaline Phosphatase - blood
/ Alkaline Phosphatase - drug effects
/ Antigens
/ Antineoplastic Agents - therapeutic use
/ castration-resistant prostate cancer
/ Humans
/ Male
/ Prostatic Neoplasms, Castration-Resistant - blood
/ Prostatic Neoplasms, Castration-Resistant - drug therapy
/ Prostatic Neoplasms, Castration-Resistant - pathology
/ survival
